nach oben

CNS Drugs

Erschienen in:

01.02.2009 | Review Article

Antiepileptic Drug-Induced Cognitive Adverse Effects

Potential Mechanisms and Contributing Factors

verfasst von: Dr Marco Mula, Michael R. Trimble

Erschienen in: CNS Drugs | Ausgabe 2/2009

Einloggen, um Zugang zu erhalten

Abstract

Cognitive dysfunction is frequently observed in patients with epilepsy and represents an important challenge in the management of patients with this disorder. In this respect, the relative contribution of antiepileptic drugs (AEDs) is of relevance. The fact that a considerable number of patients require AED therapy for many years, or perhaps even a lifetime, emphasizes the need to focus on the long-term adverse effects of these drugs on cognition.

The most prevalent of the CNS adverse effects observed during AED therapy are sedation, somnolence, distractibility, insomnia and dizziness. Sedation, in particular, is associated with most of the commonly used AED therapies. Nevertheless, cognitive function in individuals with epilepsy may also be influenced by several factors, of which AEDs constitute only one of many putative causes.

In general terms, most studies agree that some differences exist among the older AEDs with regard to the effects on cognition, and some newer generation molecules may have a better cognitive profile than older AEDs. The mechanisms of action are an obvious determinant; however, there is still a lack of evidence for differentiation between available drugs with regard to cognitive effects. Some authors have suggested that there may be different cognitive effects associated with individual drugs; however, the question as to whether there are more specific deficits related to the action of individual drugs remains unsolved.

There seems to be agreement that polytherapy and high-dose treatment can produce cognitive adverse effects and when high dosages or adjunctive polytherapy is needed, the balance between benefits and disadvantages may be negatively biased against drug treatment. Thus, drug treatment requires careful balancing in the attempt to reach maximal seizure control while avoiding neurotoxic adverse effects.

Finally, the mood status of the patient and clinical relevance of the information obtained by neuropsychological testing represent important variables that need to be taken into account when discussing cognitive adverse effects of AEDs.

Meador KJ. Cognitive and memory effects of the new anti-epileptic drugs. Epilepsy Res 2006; 68: 63–7PubMedCrossRef

Trimble MR, Dodson WE. Epilepsy and quality of life. New York: (Raven Press, 1994

Perucca E. Withdrawing antiepileptic drugs in seizure-free patients: what are the cognitive benefits? Nat Clin Pract Neurol 2007; 3: 194–5PubMedCrossRef

Thompson PJ, Trimble MR. Further studies on anticonvulsant drugs and seizures. Acta Neurol Scand Suppl 1981; 89: 51–8PubMed

Thompson PJ, Trimble MR. Sodium valproate and cognitive functioning in normal volunteers. Br J Clin Pharmacol 1981; 12: 819–24PubMedCrossRef

Aldenkamp AP. Effects of antiepileptic drugs on cognition. Epilepsia 2001; 42Suppl. 1: 46–9PubMedCrossRef

Brunbech L, Sabers A. Effect of antiepileptic drugs on cognitive function in individuals with epilepsy: a comparative review of newer versus older agents. Drugs 2002; 62: 593–604PubMedCrossRef

Ortinski P, Meador KJ. Cognitive side effects of antiepileptic drugs. Epilepsy Beha 2004; 5Suppl. 1: S60–5CrossRef

Aldenkamp AP. Antiepileptic drug treatment and epileptic seizures: effects on cognitive function. In: Trimble MR, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002: 256–65CrossRef

10.

MacLeod CM, Dekabian AS, Hunt E. Memory impairment in epileptic patients: selective effects of phenobarbital concentration. Science 1978; 202: 1102–4PubMedCrossRef

11.

Gallassi R, Morreale A, Di Sarro R, et al. Cognitive effects of antiepileptic drug discontinuation. Epilepsia 1992; 33Suppl. 6: S41–4PubMed

12.

Vining EP, Mellitis ED, Dorsen MM, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics 1987; 80: 165–74PubMed

13.

Calandre EP, Dominguez-Granados R, Gomez-Rubio M, et al. Cognitive effects of long-term treatment with phenobarbital and valproic acid in school children. Acta Neurol Scand 1990; 81: 504–6PubMedCrossRef

14.

Meador KJ, Loring DW, Huh K, et al. Comparative cognitive effects of anticonvulsants. Neurology 1990; 40: 391–4PubMedCrossRef

15.

Smith WL, Lowrey JB. Effects of diphenylhydantoin on mental abilities in the elderly. J Am Geriatr Soc 1975; 23: 207–11PubMed

16.

Thompson P, Huppert F, Trimble M. Anticonvulsant drugs, cognitive function and memory. Acta Neurol Scand Suppl 1980; 80: 75–81PubMed

17.

Thompson P, Huppert FA, Trimble M. Phenytoin and cognitive function: effects on normal volunteers and implications for epilepsy. Br J Clin Psychol 1981; 20: 155–62PubMedCrossRef

18.

Meador KJ, Loring DW, Allen ME, et al. Comparative cognitive effects of carbamazepine and phenytoin in healthy adults. Neurology 1991; 41: 1537–40PubMedCrossRef

19.

Meador KJ, Loring DW, Abney OL, et al. Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. Epilepsia 1993; 34: 153–7PubMedCrossRef

20.

Forsythe I, Butler R, Berg I, et al. Cognitive impairment in new cases of epilepsy randomly assigned to carbamazepine, phenytoin and sodium valproate. Dev Med Child Neurol 1991; 33: 524–34PubMedCrossRef

21.

Thompson PJ, Trimble MR. Anticonvulsant drugs and cognitive functions. Epilepsia 1982; 23: 531–44PubMedCrossRef

22.

Craig I, Tallis R. Impact of valproate and phenytoin on cognitive function in elderly patients: results of a single-blind randomized comparative study. Epilepsia 1994; 35: 381–90PubMedCrossRef

23.

Prevey ML, Delaney RC, Cramer JA, et al. Effect of valproate on cognitive functioning: comparison with carbamazepine. The Department of Veterans Affairs Epilepsy Cooperative Study 264 Group. Arch Neurol 1996; 53: 1008–16

24.

Meador KJ, Loring DW, Hulihan JF, et al. Differential cognitive and behavioral effects of topiramate and valproate. Neurology 2003; 60: 1483–8PubMedCrossRef

25.

Remy C, Beaumont D. Efficacy and safety of vigabatrin in the long-term treatment of refractory epilepsy. Br J Clin Pharmacol 1989; 27Suppl. 1: 125–9SCrossRef

26.

Tartara A, Manni R, Galimberti CA, et al. Vigabatrin in the treatment of epilepsy: a long-term follow-up study. J Neurol Neurosurg Psychiatry 1989; 52: 467–71PubMedCrossRef

27.

Ylinen A, Kalviainen R, Riekkinen Sr SJ. Long-term efficacy and cognitive effects of vigabatrin. Acta Neurol Scand Suppl 1995; 162: 47–50PubMed

28.

McGuire AM, Duncan JS, Trimble MR. Effects of vigabatrin on cognitive function and mood when used as addon therapy in patients with intractable epilepsy. Epilepsia 1992; 33: 128–34PubMedCrossRef

29.

Gillham RA, Blacklaw J, McKee PJ, et al. Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. J Neurol Neurosurg Psychiatry 1993; 56: 1271–5PubMedCrossRef

30.

Dodrill CB, Arnett JL, Sommerville KW, et al. Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology 1993; 43: 2501–7PubMedCrossRef

31.

Provinciali L, Bartolini M, Mari F, et al. Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurol Scand 1996; 94: 12–8PubMedCrossRef

32.

Monaco F, Torta R, Cicolin A, et al. Lack of association between vigabatrin and impaired cognition. J Int Med Res 1997; 25: 296–301PubMed

33.

Dodrill CB, Arnett JL, Sommerville KW, et al. Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia 1995; 36: 164–73PubMedCrossRef

34.

Kalviainen R, Aikia M, Saukkonen AM, et al. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized, controlled study. Arch Neurol 1995; 52: 989–96PubMedCrossRef

35.

Aikia M, Kalviainen R, Sivenius J, et al. Cognitive effects of oxcarbazepine and phenytoin monotherapy in newly diagnosed epilepsy: one year follow-up. Epilepsy Res 1992; 11: 199–203PubMedCrossRef

36.

Sabers A, Moller A, Dam M, et al. Cognitive function and anticonvulsant therapy: effect of monotherapy in epilepsy. Acta Neurol Scand 1995; 92: 19–27PubMedCrossRef

37.

Banks GK, Beran RG. Neuropsychological assessment in lamotrigine treated epileptic patients. Clin Exp Neurol 1991; 28: 230–7PubMed

38.

Placidi F, Marciani MG, Diomedi M, et al. Effects of lamotrigine on nocturnal sleep, daytime somnolence and cognitive functions in focal epilepsy. Acta Neurol Scand 2000; 102: 81–6PubMedCrossRef

39.

Blum D, Meador K, Biton V, et al. Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006; 67: 400–6PubMedCrossRef

40.

Leach JP, Girvan J, Paul A, et al. Gabapentin and cognition: a double blind, dose ranging, placebo controlled study in refractory epilepsy. J Neurol Neurosurg Psychiatry 1997; 62: 372–6PubMedCrossRef

41.

Dodrill CB, Arnett JL, Hayes AG, et al. Cognitive abilities and adjustment with gabapentin: results of a multisite study. Epilepsy Res 1999; 35: 109–21PubMedCrossRef

42.

Sveinbjornsdottir S, Sander JW, Patsalos PN, et al. Neuropsychological effects of tiagabine, a potential new anti-epileptic drug. Seizure 1994; 3: 29–35PubMedCrossRef

43.

Kalviainen R, Aikia M, Mervaala E, et al. Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy. Epilepsy Res 1996; 25: 291–7PubMedCrossRef

44.

Dodrill CB, Arnett JL, Sommerville KW, et al. Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy. Neurology 1997; 48: 1025–31PubMedCrossRef

45.

Dodrill CB, Arnett JL, Shu V, et al. Effects of tiagabine monotherapy on abilities, adjustment, and mood. Epilepsia 1998; 39: 33–42PubMedCrossRef

46.

Dodrill CB, Arnett JL, Deaton R, et al. Tiagabine versus phenytoin and carbamazepine as add-on therapies: effects on abilities, adjustment, and mood. Epilepsy Res 2000; 42: 123–32PubMedCrossRef

47.

Fritz N, Glogau S, Hoffmann J, et al. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy Behav 2005; 6: 373–81PubMedCrossRef

48.

Burton LA, Harden C. Effect of topiramate on attention. Epilepsy Res 1997; 27: 29–32PubMedCrossRef

49.

Thompson PJ, Baxendale SA, Duncan JS, et al. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000; 69: 636–41PubMedCrossRef

50.

Lee HW, Jung DK, Suh CK, et al. Cognitive effects of low-dose topiramate monotherapy in epilepsy patients: a 1-year follow-up. Epilepsy Behav 2006; 8: 736–41PubMedCrossRef

51.

Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000; 41: 1167–78PubMedCrossRef

52.

Neyens LG, Alpherts WC, Aldenkamp AP. Cognitive effects of a new pyrrolidine derivative (levetiracetam) in patients with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry 1995; 19: 411–9PubMedCrossRef

53.

Gomer B, Wagner K, Frings L, et al. The influence of anti-epileptic drugs on cognition: a comparison of levetiracetam with topiramate. Epilepsy Behav 2007; 10: 486–94PubMedCrossRef

54.

Berent S, Sackellares JC, Giordani B, et al. Zonisamide (CI-912) and cognition: results from preliminary study. Epilepsia 1987; 28: 61–7PubMedCrossRef

55.

Park SP, Hwang YH, Lee HW, et al. Long-term cognitive and mood effects of zonisamide monotherapy in epilepsy patients. Epilepsy Behav 2008; 12: 102–8PubMedCrossRef

56.

Ciesielski AS, Samson S, Steinhoff BJ. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav 2006; 9: 424–31PubMedCrossRef

57.

Aldenkamp AP, Dreifuss FE, Reiner WO. Epilepsy in children and adolescents. New York: CRC Publishers, 1995

58.

Stewart SA. The effects of benzodiazepines on cognition. J Clin Psychiatry 2005; 66Suppl. 2: 9–13PubMed

59.

Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Eighth Eilat Conference (EILAT VIII). Epilepsy Res 2007; 73: 1–52PubMedCrossRef

60.

Rogawski MA, Löscher W. The neurobiology of anti-epileptic drugs. Nat Rev Neurosci 2004; 5: 553–64PubMedCrossRef

61.

Salinsky MC, Storzbach D, Spencer DC, et al. Effects of topiramate and gabapentin on cognitive abilities in healthy volunteers. Neurology 2005; 64: 792–8PubMedCrossRef

62.

Meador KJ, Loring DW, Vahle VJ, et al. Cognitive and behavioral effects of lamotrigine and topiramate in healthy volunteers. Neurology 2005; 64: 2108–14PubMedCrossRef

63.

Trimble MR. Anticonvulsant drugs and cognitive function: a review of the literature. Epilepsia 1987; 28Suppl. 3: S37–45PubMedCrossRef

64.

Reynolds EH. Neurological aspects of folate and vitamin B12 metabolism. Clin Haematol 1976; 5: 661–96PubMed

65.

Reynolds EH, Carney MW, Toone BK. Methylation and mood. Lancet 1984; 2: 196–8PubMedCrossRef

66.

Dodrill CB. Correlates of generalized tonic-clonic seizures with intellectual, neuropsychological, emotional, and social function in patients with epilepsy. Epilepsia 1986; 27: 399–411PubMedCrossRef

67.

Aldenkamp AP, Bodde N. Behaviour cognition and epilepsy. Acta Neurol Scand Suppl 2005; 182: 19–25PubMedCrossRef

68.

Pincus JH, Tucker GJ. Behavioral neurology. 4th ed. Oxford: Oxford University Press, 2003: 24–5

69.

Loiseau P, Strube E, Signoret JL. Memory and epilepsy. In: Trimble MR, Reynolds EH, editors. Epilepsy, behaviour and cognitive function. New York: John Wiley & Sons, 1988: 165–77

70.

Binnie CD. Cognitive impairment during epileptiform discharges: is it ever justifiable to treat the EEG? Lancet Neurol 2003; 2: 725–30PubMedCrossRef

71.

Jokeit H, Ebner A. The risk of cognitive decline in patients with refractory temporal lobe epilepsy. In: Trimble MR, Schmitz B, editors. The neuropsychiatry of epilepsy. Cambridge: Cambridge University Press, 2002: 152–63CrossRef

72.

Gordon N. The Landau-Kleffner syndrome: increased understanding. Brain Dev 1997; 19: 311–6PubMedCrossRef

73.

Baxendale SA, van Paesschen W, Thompson PJ, et al. The relationship between quantitative MRI and neuro-psychological functioning in temporal lobe epilepsy. Epilepsia 1998; 39: 158–66PubMedCrossRef

74.

Helmstaedter C. Behavioral aspects of frontal lobe epilepsy. Epilepsy Behav 2001; 2: 384–95PubMedCrossRef

75.

Mula M, Trimble MR, Thompson P, et al. Topiramate and word-finding difficulties in patients with epilepsy. Neurology 2003; 60: 1104–7PubMedCrossRef

76.

Kanner AM, Wuu J, Faught E, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav 2003; 4: 548–52PubMedCrossRef

77.

Mula M, Trimble MR, Sander JW. The role of hippocampal sclerosis in topiramate-related depression and cognitive deficits in people with epilepsy. Epilepsia 2003; 44: 1573–7PubMedCrossRef

78.

Herrmann DJ. Know the memory: the use of questionnaires to assess and study memory. Psychol Bull 1982; 92: 434–52CrossRef

79.

Thompson PJ. Epilepsy and memory. In: Manelis J, Bental E, Loeber EN, et al., editors. Advances in epileptology. Vol. 17. New York: Raven Press, 1989

80.

Aldenkamp AP, Baker G, Pieters MS, et al. The neuro-toxicity scale: the validity of a patient-based scale, assessing neurotoxicity. Epilepsy Res 1995; 20: 229–39PubMedCrossRef

81.

Aldenkamp AP, Baker GA. The neurotoxicity scale: II. Results of a patient-based scale assessing neurotoxicity in patients with epilepsy. Epilepsy Res 1997; 27: 165–73

82.

Dodrill CB, Troupin AS. Neuropsychological effects of carbamazepine and phenytoin: a reanalysis. Neurology 1991; 41: 141–3PubMedCrossRef

83.

Herranz JL, Arteaga R, Armijo JA. Side effects of sodium valproate in monotherapy controlled by plasma levels: a study in 88 pediatric patients. Epilepsia 1982; 23: 203–14PubMedCrossRef

84.

Aldenkamp AP, Alpherts WC, Moerland MC, et al. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia 1987; 28: 507–14PubMedCrossRef

85.

Pieters MS, Jennekens-Schinkel A, Stijnen T, et al. Carbamazepine (CBZ) controlled release compared with conventional CBZ: a controlled study of attention and vigilance in children with epilepsy. Epilepsia 1992 Nov–Dec; 3(6): 1137–44CrossRef

86.

Brouwer OF, Pieters MS, Edelbroek PM, et al. Conventional and controlled release valproate in children with epilepsy: a cross-over study comparing plasma levels and cognitive performances. Epilepsy Res 1992; 13: 245–53PubMedCrossRef

87.

Bialer M. Extended-release formulations for the treatment of epilepsy. CNS Drugs 2007; 21(9): 765–74PubMedCrossRef

88.

Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007 Oct; 48(10): 1825–32PubMedCrossRef

89.

Aldenkamp AP, Rentmeester T, Hulsman J, et al. Pharmaco-kinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur J Clin Pharmacol 1998; 54: 185–92PubMedCrossRef

90.

Perucca E. Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age. Clin Pharmacokinet 2006; 45: 351–63PubMedCrossRef

91.

Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 4Suppl. 2: S25–38PubMedCrossRef

92.

Bergin AM. Pharmacotherapy of paediatric epilepsy. Expert Opin Pharmacother 2003; 4: 421–31PubMedCrossRef

93.

Loring DW, Meador KJ. Cognitive side effects of antiepileptic drugs in children. Neurology 2004; 62: 872–7PubMedCrossRef

94.

Vinten J, Adab N, Kini U, et al. Neuropsychological effects of exposure to anticonvulsant medication in utero. Neurology 2005; 64: 949–54PubMedCrossRef

95.

Meador KJ, Baker G, Cohen MJ, et al. Cognitive/ behavioral teratogenetic effects of antiepileptic drugs. Epilepsy Behav 2007; 11: 292–302PubMedCrossRef

96.

Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999; 21: 101–22PubMedCrossRef

97.

Drane DL, Meador KJ. Epilepsy anticonvulsant drugs and cognition. Baillieres Clin Neurol 1996; 5: 877–85PubMed

98.

Butler CR, Graham KS, Hodges JR, et al. The syndrome of transient epileptic amnesia. Ann Neurol 2007; 61: 587–98PubMedCrossRef

99.

Vermeulen J, Aldenkamp AP. Cognitive side-effects of chronic antiepileptic drug treatment: a review of 25 years of research. Epilepsy Res 1995; 22: 65–95PubMedCrossRef

100.

Cochrane HC, Marson AG, Baker GA, et al. Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards. Epilepsia 1998; 39: 1088–97PubMedCrossRef

101.

Dodrill CB. A neuropsychological battery for epilepsy. Epilepsia 1978; 19: 611–23PubMedCrossRef

102.

Alpherts WC, Aldenkamp AP. Computerized neuropsychological assessment of cognitive functioning in children with epilepsy. Epilepsia 1990; 31Suppl. 4: S35–40PubMedCrossRef

103.

Fliessbach K, Hoppe C, Schlegel U, et al. NeuroCogFX: a computer-based neuropsychological assessment battery for the follow-up examination of neurological patients [in German]. Fortschr Neurol Psychiatr 2006; 74: 643–50PubMedCrossRef

104.

McCaffrey RJ, Westervelt HJ. Issues associated with repeated neuropsychological assessments. Neuropsychol Rev 1995; 5: 203–21PubMedCrossRef

105.

Seidenberg M, O’Leary DS, Giordani B, et al. Test-retest IQ changes of epilepsy patients: assessing the influence of practice effects. J Clin Neuropsychol 1981; 3: 237–55PubMedCrossRef

106.

Austin JK, Huberty TJ, Huster GA, et al. Does academic achievement in children with epilepsy change over time? Dev Med Child Neurol 1999; 41: 473–9PubMedCrossRef

107.

Dreifuss FE. Cognitive function: victim of disease or hostage to treatment? Epilepsia 1992; 33Suppl. 1: S7–12PubMedCrossRef

Titel: Antiepileptic Drug-Induced Cognitive Adverse Effects
Potential Mechanisms and Contributing Factors
verfasst von: Dr Marco Mula
Michael R. Trimble
Publikationsdatum: 01.02.2009
Verlag: Springer International Publishing
Erschienen in: CNS Drugs / Ausgabe 2/2009
Print ISSN: 1172-7047
Elektronische ISSN: 1179-1934
DOI: https://doi.org/10.2165/00023210-200923020-00003

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2009

Assessing Residual Confounding of the Association between Antipsychotic Medications and Risk of Death using Survey Data

Current Considerations in the Treatment of Generalized Anxiety Disorder

Dopamine Dysregulation Syndrome

Role of Antiepileptic Drugs in the Management of Eating Disorders